Ginkgo Bioworks Announces Date of Fourth Quarter and Full Year 2025 Results Presentation

Ginkgo Bioworks Announces Date of Fourth Quarter and Full Year 2025 Results Presentation

Presentation and Q&A session scheduled for post-market on Thursday, February 26, 2026

Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo") today announced that it plans to host a presentation and Q&A session reviewing business performance for the fourth quarter and full year ended December 31, 2025, on Thursday, February 26, 2026, beginning at 4:30 p.m. ET.

The presentation details and webcast link will be available on Ginkgo's investor relations website at https://investors.ginkgobioworks.com, and a replay will be made available.

To ask a question ahead of the presentation, please submit them to @Ginkgo on X (hashtag #GinkgoResults) or by sending an e-mail to investors@ginkgobioworks.com.

About Ginkgo Bioworks
Ginkgo Bioworks builds the tools that make biology easier to engineer for everyone. The company offers autonomous laboratories that replace manual laboratory work with robotics in the lab, greatly improving the productivity of scientists. Ginkgo's in-house autonomous lab is also available as a "cloud lab" through our Datapoints and Solutions contract research services. For more information, visit ginkgobioworks.com and ginkgobiosecurity.com, read our blog, or follow us on social media channels such as X (@Ginkgo and @Ginkgo_Biosec), Instagram (@GinkgoBioworks), Threads (@GinkgoBioworks), or LinkedIn.

Ginkgo Bioworks Contacts:

INVESTOR CONTACT:

investors@ginkgobioworks.com

MEDIA CONTACT:

press@ginkgobioworks.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/ginkgo-bioworks-announces-date-of-fourth-quarter-and-full-year-2025-results-presentation-302691775.html

SOURCE Ginkgo Bioworks

News Provided by PR Newswire via QuoteMedia

DNA
The Conversation (0)
CHARBONE Unveils its 2026-2030 Strategic Plan: A Transformation Towards an Integrated High-Value Industrial Gas Group

CHARBONE Unveils its 2026-2030 Strategic Plan: A Transformation Towards an Integrated High-Value Industrial Gas Group

Charbone CORPORATION (TSXV: CH,OTC:CHHYF; OTCQB: CHHYF; FSE: K47) ("Charbone" or the "Company"), a North American producer and distributor specializing in clean Ultra High Purity ("UHP") hydrogen and strategic industrial gases, today announced the rollout of its comprehensive 2026-2030 strategic... Keep Reading...
QIAGEN to discontinue NeuMoDx integrated PCR testing system, support customers during transition period

QIAGEN to discontinue NeuMoDx integrated PCR testing system, support customers during transition period

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a decision to discontinue the NeuMoDx 96 and 288 Molecular Systems in light of the market development trends for these product lines following the COVID-19 pandemic and changing customer needs for integrated PCR-based clinical... Keep Reading...
QIAGEN launches digital PCR Assay Design Tool for QIAcuity, expands customization capabilities of its research platform GeneGlobe

QIAGEN launches digital PCR Assay Design Tool for QIAcuity, expands customization capabilities of its research platform GeneGlobe

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of its new digital PCR (dPCR) Custom Assay Design Tool for copy number variation (CNV) analysis for use on its digital PCR platform QIAcuity and several other enhancements in its GeneGlobe Design and Analysis Hub, a... Keep Reading...
Aligos Therapeutics Presents Positive Data at the EASL Congress 2024

Aligos Therapeutics Presents Positive Data at the EASL Congress 2024

Aligos Therapeutics, Inc. (Nasdaq: ALGS, "Aligos"), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced positive data from six poster presentations at the European Association for the... Keep Reading...

Interactive Chart

Latest Press Releases

Related News